Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Agilent, Seoul University To Establish New Research Center | Contract Pharma
Breaking News, Collaborations & Alliances

Agilent, Seoul University To Establish New Research Center

Will provide drug development from identification through to clinical trial testing

Agilent Technologies, Inc. has entered a collaboration with Seoul National University for a new research center that will support the College of Pharmacy’s New Drug Development Center. The collaboration will conduct drug metabolism studies and research to evaluate and develop new compounds, as well as assess toxicity and pharmacokinetics, and conduct clinical tests for drugs.
 
Agilent will provide bioanalytical instruments and expertise for drug testing and multi-omic biological systems. The jointly established research center will also serve as Agilent’s reference site for drug development. This new multi-purpose research center will house facilities for analysis, efficacy testing, medicinal ingredient research, as well as a medicinal chemistry lab.
 
“One of the megatrends fueling life science research is the aging population,” said Agilent’s Rod Minett, general manager, Life Sciences, South Korea and South Asia-Pacific region. “Through continual research, trials and developments, we believe that newer, more effective drugs can be developed. As such, Agilent is pleased to support SNU College of Pharmacy’s drive to create better drugs for a safer and healthier population.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters